Spexis AG

SIX:SPEX.SW

$0.057 CHF

$0.01 (11.76%)

Volume
50.26K
Average Volume
288.6K
Market Capitalization
$3.86M
P/E Ratio
Dividend Yield
%
Price Target
$
Year High
$1.06
Year Low
$0.01
Payout Ratio
$
Current Ratio
$

Industry, Sector & symbol

Stock Exchange Swiss Exchange
CEO Dr. Jeffrey David Wager
Industry Biotechnology
Sector Healthcare
Current Symbol SPEX.SW
CUSIP None
CIK None
Web https://spexisbio.com
Phone 41 61 567 16 00
Currency CHF
Employees 50
Country CH

Liquidity

Debt-to-Equity Ratio
Payout Ratio
Current Ratio
Quick Ratio
Cash Ratio

Sales & Book Value

Annual Sales $-
Price / Sales
Cash Flow
Price / Cash Flow
Price / Book

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating
Rating Score(0-5)
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $
Trailing P/E Ratio
PEG Ratio
P/E Growth
Net Income $-
Net Margin %
Pretax Margin %
Return on Equity %
Return on Assets %

Financials Score

AltmanZ Score
Piotroski Score
Working Capital -
Total Assets -
Ebit -
Market Cap -
Total Liabilities -

Poll Results

About Spexis AG (SIX:SPEX.SW) Stock

Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. Spexis ... AG is headquartered in Allschwil, Switzerland.

Frequently Asked Questions

What is the current Spexis AG (SPEX.SW) stock price?

Spexis AG(SIX:SPEX.SW) stock price is $0.057 in the last trading session. During the trading session, SPEX.SW stock reached the peak price of $1.06 while $0.0122 was the lowest point it dropped to. The percentage change in SPEX.SW stock occurred in the recent session was 11.76% while the dollar amount for the price change in SPEX.SW stock was $0.01.

SPEX.SW's industry and sector of operation?

The SIX listed SPEX.SW is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of SPEX.SW?

Mr. Gokhan Batur | Executive Officer
Dr. Goncalo Bernardes | Acting Head of Chemical Biology
Dr. Jeffrey David Wager | President, Chief Executive Officer, Treasurer, Chairman & Secretary
Dr. Juergen Froehlich FCPh, M.D., MBA | Chief Medical & Development Officer
Muriel Fleming | Head of Human Resources

How many employees does SPEX.SW have?

Number of SPEX.SW employees currently stands at 50. SPEX.SW operates from Hegenheimermattweg 125, Allschwil, None 4123, CH.

Link for SPEX.SW official website?

Official Website of SPEX.SW is: https://spexisbio.com

How do I contact SPEX.SW?

SPEX.SW could be contacted at phone #41 61 567 16 00 and can also be accessed through its website. SPEX.SW operates from Hegenheimermattweg 125, Allschwil, None 4123, CH.

How many shares of SPEX.SW are traded daily?

The average number of SPEX.SW shares traded daily for last 3 months was 288.6K.

What is the market cap of SPEX.SW currently?

The market value of SPEX.SW currently stands at $3.86M with its latest stock price at $0.057